Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PSMA/CD70 Bi-specific CAR-T Cells for Cancer Treatment
NCT05437341Phase 2Terminated
- Sponsor
- Shenzhen Geno-Immune Medical Institute
- Start
- Jun 2026
- Primary completion
- Jul 2026
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of bi-4SCAR-PSMA/CD70 T cells in cancer, sponsored by Shenzhen Geno-Immune Medical Institute. Started Jun 2026; status: terminated.
02
Drugs
bi-4SCAR-PSMA/CD70 T cells
03
Conditions
cancer
Beyond the preview
Go deeper on NCT05437341.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05437341.